Drug name - Fintepla
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10947183 | ZOGENIX INC | Fenfluramine compositions and methods of preparing the same |
Dec, 2036
(14 years from now) | |
| CN108883399A | ZOGENIX INC | Fenfluramine Composition And Preparation Method Thereof |
Dec, 2036
(14 years from now) | |
| CN108883399B | ZOGENIX INC | Faffluramine Composition And Preparation Method Thereof |
Dec, 2036
(14 years from now) | |
| EP3393655A4 | ZOGENIX INC | Fenfluramine Compositions And Methods Of Preparing The Same |
Dec, 2036
(14 years from now) | |
| EP3393655A1 | ZOGENIX INC | Fenfluramine Compositions And Methods Of Preparing The Same |
Dec, 2036
(14 years from now) | |
| EP3393655B1 | ZOGENIX INC | Fenfluramine Compositions And Methods Of Preparing The Same |
Dec, 2036
(14 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10478442 | ZOGENIX INC | Method for the treatment of Dravet Syndrome |
May, 2033
(10 years from now) | |
| US9603815 | ZOGENIX INC | Method for the treatment of Dravet syndrome |
May, 2033
(10 years from now) | |
| US9549909 | ZOGENIX INC | Method for the treatment of dravet syndrome |
May, 2033
(10 years from now) | |
| US10478441 | ZOGENIX INC | Method for the treatment of Dravet syndrome |
May, 2033
(10 years from now) | |
| US9610260 | ZOGENIX INC | Method for the treatment of Dravet Syndrome |
May, 2033
(10 years from now) | |
| US9603814 | ZOGENIX INC | Method for the treatment of Dravet syndrome |
May, 2033
(10 years from now) | |
| US10950331 | ZOGENIX INC | Control system for control of distribution of medication |
Sep, 2035
(13 years from now) | |
| US10603290 | ZOGENIX INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Aug, 2037
(14 years from now) | |
| US11040018 | ZOGENIX INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Aug, 2037
(14 years from now) | |
| US10452815 | ZOGENIX INC | Control system for control of distribution of medication |
Jun, 2038
(15 years from now) | |
Drugs and Companies using FENFLURAMINE HYDROCHLORIDE ingredient
Treatment: Use in combination with stiripentol for the treatment of seizures associated with dravet syndrome; Use in combination with stiripentol, valproate, and clobazam for the treatment of seizures associated with dravet syndrome; Treatment of refractory epilepsy patients with fenfluramine that reduces the risk of cardiovascular toxicity by using cardiac monitoring and restricted distribution; Use in combination with cannabidiol for the treatment of seizures associated with dravet syndrome; Use of cardiac monitoring and restricted distribution of fenfluramine to mitigate risk of cardiovascular toxicity in the treatment of seizures associated with dravet syndrome
Dosage: SOLUTION;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 2.2MG BASE/ML | SOLUTION;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.